SAFETY and IMMUNOGENICITY of BNT162B2 MRNA COVID-19 VACCINE among ADOLESCENTS with RHEUMATIC DISEASES TREATED with IMMUNOMODULATORY MEDICATIONS
Annals of the Rheumatic Diseases
; 81:370-371, 2022.
Article
in English
| EMBASE | ID: covidwho-2009138
ABSTRACT
Background:
Adolescents with juvenile-onset autoimmune infammatory rheumatic diseases (AIIRD) could be at risk for disease fare secondary to SARS-CoV-2 infection or to withholding anti-infammatory therapy. While vaccination can protect against COVID-19, safety and immunogenicity data regarding anti-SARS-CoV-2 vaccines among adolescents with AIIRD are limited.Objectives:
This international, prospective, multicentre study evaluated the safety and immunogenicity of the BNT162b2 anti-SARS-CoV-2 vaccine among adolescents and young adults with juvenile-onset AIIRD, 80% of whom are on chronic immunomodulatory therapy.Methods:
Vaccine side effects, disease activity, and short-term efficacy were evaluated after 3 months in 91 patients. Anti-spike S1/S2 IgG antibody levels were evaluated in 37 patients and 22 controls, 2-9 weeks after the second dose.Results:
Ninety-one patients and 40 healthy controls were included. Safety pro-file was good, with 96.7% (n=88) of patients reporting mild or no side-effects, and no change in disease activity. However, 3 patients had transient acute symptoms 2 following the frst vaccination (renal failure and pulmonary haemorrhage) and 1 following the second dose (mild lupus fare vs. viral infection). Seropositivity rate was 97.3% in the AIIRD group compared with 100% among controls. However, anti-S1/S2 antibody titres were signifcantly lower in the AIIRD group compared with controls (242±136.4 vs. 387.8±57.3 BAU/ml, respectively;p<0.0001). No cases of COVID-19 were documented during the 3-month follow-up.Conclusion:
Vaccination of juvenile-onset AIIRD patients demonstrated good short-term safety and efficacy, high seropositivity rate, but lower anti-S1/S2 antibody titres compared to healthy controls. These results should encourage vaccination of adolescents with juvenile-onset AIIRD, even while on immunomodulation.
immunoglobulin G antibody; tozinameran; adolescent; adult; antibody titer; clinical evaluation; conference abstract; coronavirus disease 2019; drug safety; female; follow up; human; immunogenicity; immunomodulation; immunotherapy; juvenile; kidney failure; lung hemorrhage; major clinical study; male; multicenter study; prospective study; rheumatic disease; side effect; spike; systemic lupus erythematosus; vaccination; vaccination reaction; young adult
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Vaccines
Language:
English
Journal:
Annals of the Rheumatic Diseases
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS